Abstract: The present invention relates to a compound capable of lowering the flammability of a non-aqueous electrolyte when included in the non-aqueous electrolyte and improving the life properties of a battery by forming an electrode-electrolyte interface which is stable at high temperatures and low in resistance, and relates to a compound represented by Formula I descried herein, a non-aqueous electrolyte solution and a lithium secondary battery both including the compound, n, m, Ak, and X are described herein.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A method of screening a skin whitening agent uses the stromal cell-derived factor 1 (SDF1) promoter region, the correlation between the expression amount of the skin pigment and the expression of the SDF1 promoter is observed and thus it is expected to be available in systems for pre-screening pigmentation substances and pigment reduction materials, and the drugs screened by the method is used for treatment of skin pigment-related diseases.

Abstract: A method of screening a skin whitening agent uses the stromal cell-derived factor 1 (SDF1) promoter region, the correlation between the expression amount of the skin pigment and the expression of the SDF1 promoter is observed and thus it is expected to be available in systems for pre-screening pigmentation substances and pigment reduction materials, and the drugs screened by the method is used for treatment of skin pigment-related diseases.

Abstract: A method of preventing or treating cutaneous pigmentation disease in a subject in need thereof, includes: providing a pharmaceutical composition comprising SDF1, an inducer or activator of SDF1, as an active ingredient; and administering the pharmaceutical composition to the subject, wherein the cutaneous pigmentation is prevented or treated, and the cutaneous pigmentation disease is selected from the group consisting of melasma, freckles, lentigo, nevus, pigmentation by drugs, pigmentation after inflammation and hyperpigmentation incurred from dermatitis.

Abstract: A method of preventing or treating cutaneous pigmentation disease in a subject in need thereof, includes: providing a pharmaceutical composition comprising SDF1, an inducer or activator of SDF1, as an active ingredient; and administering the pharmaceutical composition to the subject, wherein the cutaneous pigmentation is prevented or treated, and the cutaneous pigmentation disease is selected from the group consisting of melasma, freckles, lentigo, nevus, pigmentation by drugs, pigmentation after inflammation and hyperpigmentation incurred from dermatitis.

Abstract: There is provided a red phosphor that may include a nitride represented by a formula of (Sr1-x-yBaxEuy)2Si5N8, wherein 0<x<0.7, and 0<y<0.1. The red phosphor may emit light having a peak wavelength in a range of 600 nm to 630 nm when irradiated by an excitation source and the excitation source may be a blue light source having a dominant wavelength in a range of 420 nm to 470 nm.

Abstract: A red phosphor contains a nitride having a formula of SrxMgySizN2/3(x+y+2z+w):Euw, in which x, y, z, and w satisfy the relationships 0.5?x?2, 2.5?y?3.5, 0.5?z?1.5 and 0<w?0.1. The red phosphor is configured to emit light having a peak wavelength in a range of from 610 nm to 625 nm when irradiated by an excitation source, and the excitation source may be a blue light source having a dominant wavelength in a range of 420 nm to 470 nm. In such a case, the spectrum of the emitted light has a full-width at half-maximum (FWHM) less than or equal to 55 nm.

Abstract: A red phosphor contains a nitride having a formula of SrxMgySizN2/3(x+y+2z+w):Euw, in which x, y, z, and w satisfy the relationships 0.5?x?2, 2.5?y?3.5, 0.5?z?1.5 and 0<w?0.1. The red phosphor is configured to emit light having a peak wavelength in a range of from 610 nm to 625 nm when irradiated by an excitation source, and the excitation source may be a blue light source having a dominant wavelength in a range of 420 nm to 470 nm. In such a case, the spectrum of the emitted light has a full-width at half-maximum (FWHM) less than or equal to 55 nm.

Abstract: There is provided a red phosphor that may include a nitride represented by a formula of (Sr1?x?yBaxEuy)2Si5N8, wherein 0<x<0.7, and 0<y<0.1. The red phosphor may emit light having a peak wavelength in a range of 600 nm to 630 nm when irradiated by an excitation source and the excitation source may be a blue light source having a dominant wavelength in a range of 420 nm to 470 nm.